Tiotropium v placebo for chronic obstructive pulmonary disease at mean 6.3 months*
| Outcomes | Number of trials (n) | Weighted event rates | RRR (95% CI) | NNT (CI) | |
|---|---|---|---|---|---|
| Tiotropium | Placebo | ||||
| Exacerbations | 8 (5644) | 26% | 31% | 18% (10 to 25) | 20 (13 to 34) |
| Hospital admissions | 3 (3552) | 5.4% | 8.4% | 33% (14 to 47) | 34 (25 to 100 |
| All cause mortality | 2 (1723) | 0.6% | 1.6% | 50% (−24 to 80) | Not significant |
| RRI (CI) | NNH (CI) | ||||
|---|---|---|---|---|---|
| *Abbreviations defined in glossary; weighted event rates, RRR, RRI, NNT, NNH, and CI calculated from data in article using a fixed effects model. | |||||
| Dry mouth | 3 (1791) | 11% | 2% | 381% (109 to 672) | 12 (7 to 34) |